LIVE WIRE

← Fully Diluted database

Live wire

Live biotech news wire

Every readout, FDA decision, financing, filing and halt across the 718-stock universe, as it crosses. This page updates itself every 30 seconds; leave it open.

LIVElast updated

9:56 AM EST
QGEN
Media Inquiries
corporateir_newsrooms
9:56 AM EST
PMCB
Nov 11, 2026 PharmaCyte Biotech, Inc. Announces Reverse Stock Split
corporateir_newsrooms
9:56 AM EST
PFE
Partnering News
corporateir_newsrooms
9:56 AM EST
PFE
Update & Statements
corporateir_newsrooms
9:56 AM EST
PFE
Media Asset Library
corporateir_newsrooms
9:56 AM EST
OABI
announced the advancement of bispecific ADC (bsADC) program VXA-222
corporateir_newsrooms
9:51 AM EST
BKHA
Trading halt: $BKHAU - Black Hawk Acquisition Corpora (NASDAQ) - limit up-limit down: volatility trading pause [LUDP], still halted
haltnasdaq_halts
9:30 AM EST
BKHA
Trading halt: $BKHAU - Black Hawk Acquisition Corpora (NASDAQ) - limit up-limit down: volatility trading pause [LUDP], still halted
haltnasdaq_halts
9:02 AM EST
VNDA
NEREUS™ - The Goat of Biscayne Bay Arrives for Miami Art Week
corporatepr_newswire_health
8:56 AM EST
TPST
Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate
readoutglobenewswire
8:31 AM EST
CTXR
Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
corporatepr_newswire_all
8:31 AM EST
PRGO
Perrigo to Attend the Jefferies Miami Consumer Conference
corporatepr_newswire_all
8:31 AM EST
CTXR
Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
corporatepr_newswire_biotech
8:31 AM EST
PRGO
Perrigo to Attend the Jefferies Miami Consumer Conference
corporatepr_newswire_biotech
8:30 AM EST
PRGO
Perrigo to Attend the Jefferies Miami Consumer Conference
corporatepr_newswire_health
8:30 AM EST
CTXR
Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
corporatepr_newswire_health
8:06 AM EST
INO
INOVIO to Participate in Upcoming Investor Conferences
corporatepr_newswire_all
8:06 AM EST
INO
INOVIO to Participate in Upcoming Investor Conferences
corporatepr_newswire_biotech
8:06 AM EST
INO
INOVIO to Participate in Upcoming Investor Conferences
corporatepr_newswire_health
8:02 AM EST
TRLV
Trulieve Announces November 2026 Event Participation
corporatepr_newswire_biotech
8:02 AM EST
AMGN
AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE
readoutpr_newswire_all
8:02 AM EST
TRLV
Trulieve Announces November 2026 Event Participation
corporatepr_newswire_all
8:02 AM EST
TRLV
Trulieve Announces November 2026 Event Participation
corporatepr_newswire_health
8:01 AM EST
AMGN
AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE
readoutpr_newswire_biotech
8:00 AM EST
AMGN
AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE
readoutpr_newswire_health
7:00 AM EST
QTTB
Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London
corporatepr_newswire_all
7:00 AM EST
VTRS
Viatris to Participate in Upcoming Investor Conferences
corporatepr_newswire_all
6:59 AM EST
QTTB
Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London
corporatepr_newswire_health
6:59 AM EST
VTRS
Viatris to Participate in Upcoming Investor Conferences
corporatepr_newswire_health
6:59 AM EST
QTTB
Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London
corporatepr_newswire_biotech
6:59 AM EST
VTRS
Viatris to Participate in Upcoming Investor Conferences
corporatepr_newswire_biotech
6:02 AM EST
AMPH
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London
corporatepr_newswire_all
6:01 AM EST
AMPH
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London
corporatepr_newswire_health
6:01 AM EST
AMPH
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London
corporatepr_newswire_biotech
1:47 AM EST
ACAD
Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference
corporateir_newsrooms
1:47 AM EST
ACAD
Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal
corporateir_newsrooms
1:36 AM EST
ETON
Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms
corporateglobenewswire
1:36 AM EST
OCGN
Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN
corporateglobenewswire
1:36 AM EST
FBIO
Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
readoutglobenewswire
1:21 AM EST
IMCR
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
readoutir_newsrooms
1:21 AM EST
IMCR
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
readoutir_newsrooms
1:21 AM EST
IMCR
Immunocore reports third quarter financial results and provides a business update
corporateir_newsrooms
1:21 AM EST
IMCR
Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
readoutir_newsrooms
1:21 AM EST
IMCR
Immunocore to present at upcoming investor conferences
corporateir_newsrooms
1:21 AM EST
HYPD
Hyperion DeFi Supports DoubleZero Edge in Launching the Fastest Commercially Available Hyperliquid Data Feeds
corporateir_newsrooms
1:21 AM EST
HYPD
Hyperion DeFi Supports D3’s Frontier Vault Launch, Bringing Internet Domain Priority Access to the Hyperliquid Ecosystem
corporateir_newsrooms
1:21 AM EST
HYPD
Hyperion DeFi, Anchorage Digital, and HyperLend Together Announce the First Institutional Credit Facility on Hyperliquid
corporateir_newsrooms
1:21 AM EST
HYPD
Hyperion DeFi Commences Share Buybacks, Retires All Legacy Debt, and Commits to Further Capital Optimization
corporateir_newsrooms
1:21 AM EST
HYPD
Hyperion DeFi Schedules Third Quarter Earnings Call for Thursday, November 12 at 8:00 a.m. ET
corporateir_newsrooms
1:21 AM EST
CYRX
Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs
corporateir_newsrooms
1:21 AM EST
CYRX
Cryoport to Report Second Quarter 2026 Financial Results on August 6, 2026
corporateir_newsrooms
1:21 AM EST
CYRX
Cryoport Reports Second Quarter 2026 Financial Results
corporateir_newsrooms
1:21 AM EST
CYRX
Cryoport to Report Third Quarter 2026 Financial Results on November 5, 2026
corporateir_newsrooms
1:21 AM EST
CYRX
Cryoport Reports Third Quarter 2026 Financial Results
corporateir_newsrooms
1:16 AM EST
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
corporateir_newsrooms
1:15 AM EST
IVA
Transactions Closing
corporateir_newsrooms
1:15 AM EST
IVA
New Board Members
corporateir_newsrooms
1:15 AM EST
IVA
Eib Warrants Issuance
corporateir_newsrooms
1:15 AM EST
IVA
Preliminary Financial Results H1 2026
corporateir_newsrooms
1:15 AM EST
IVA
H1 2026 Financial Results
corporateir_newsrooms
1:15 AM EST
GERN
Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026 October 21, 2026
corporateir_newsrooms
1:15 AM EST
GERN
Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis October 28, 2026
readoutir_newsrooms
1:15 AM EST
GERN
Geron Corporation to Participate in the Stifel 2026 Healthcare Conference November 3, 2026
corporateir_newsrooms
1:15 AM EST
GERN
Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights November 4, 2026
corporateir_newsrooms
1:15 AM EST
GERN
Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026 November 4, 2026
readoutir_newsrooms
1:15 AM EST
DWTX
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
corporateir_newsrooms
1:15 AM EST
DWTX
Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
corporateir_newsrooms
1:15 AM EST
DWTX
Dogwood to Participate in the 2026 Maxim Growth Summit
corporateir_newsrooms
1:15 AM EST
DWTX
Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.
financingir_newsrooms
1:15 AM EST
DWTX
Dogwood Therapeutics Announces Third Quarter 2026 Financial Results
corporateir_newsrooms
1:10 AM EST
PMCB
May 21, 2024 PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
corporateir_newsrooms
1:10 AM EST
PMCB
Aug 18, 2025 PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
corporateir_newsrooms
1:10 AM EST
PMCB
Aug 20, 2025 PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
corporateir_newsrooms
1:10 AM EST
PMCB
Sep 2, 2025 PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
corporateir_newsrooms
1:10 AM EST
PMCB
Nov 25, 2025 PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
corporateir_newsrooms
1:07 AM EST
ENSC
Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
readoutir_newsrooms
1:07 AM EST
ENSC
Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai
corporateir_newsrooms
1:06 AM EST
PPCB
CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans Oct 22, 2026
corporateir_newsrooms
1:06 AM EST
PPCB
Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability Oct 26, 2026
corporateir_newsrooms
1:06 AM EST
PPCB
Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients Oct 28, 2026
corporateir_newsrooms
1:06 AM EST
PPCB
Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients Oct 30, 2026
corporateir_newsrooms
1:06 AM EST
PPCB
Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-β Inhibitor on TGF-β Pathway in Pancreatic Cancer Nov 2, 2026
corporateir_newsrooms
12:20 AM EST
CAPR
Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress
corporateir_newsrooms
12:20 AM EST
CAPR
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
corporateir_newsrooms
12:20 AM EST
CAPR
Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10
corporateir_newsrooms
12:20 AM EST
CAPR
Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology
readoutir_newsrooms
12:20 AM EST
CAPR
Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
corporateir_newsrooms
12:20 AM EST
ALVO
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
corporateir_newsrooms
12:20 AM EST
ALVO
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
corporateir_newsrooms
12:20 AM EST
ALVO
Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch
approvalir_newsrooms
12:20 AM EST
ALVO
Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026
corporateir_newsrooms
12:20 AM EST
ALVO
Alvotech to Present at Upcoming Investor Conferences in November
corporateir_newsrooms
12:20 AM EST
SLXN
Trading halt: $SLXNW - Silexion Therapeutics Corp W (NASDAQ) - news pending [T1], still halted
haltnasdaq_halts
12:20 AM EST
GOVX
Trading halt: $GOVX - GeoVax Labs, Inc. Cmn Stk (NASDAQ) - news pending [T1], still halted
haltnasdaq_halts
12:20 AM EST
SLXN
Trading halt: $SLXN - Silexion Therapeutics Corp OS (NASDAQ) - news pending [T1], still halted
haltnasdaq_halts
12:20 AM EST
IONS
STAT+: Ionis Pharmaceuticals shares plummet after slow rollout of biotech’s triglyceride-lowering drug
corporatestat_news
12:20 AM EST
BIIB
STAT+: Dutch antitrust regulators probe Biogen over test for its MS drug
corporatestat_news
12:20 AM EST
LLY
STAT+: Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
corporatestat_news
12:20 AM EST
NBIX
Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
corporatepr_newswire_health
12:20 AM EST
NUVB
Nuvation Bio to Present at the Jefferies Global Healthcare Conference in London
corporatepr_newswire_health

No items match the current filters.